There’s still time to contribute and attend RheumPAC’s event at ACR Convergence 2024. If you haven’t yet made your 2024 donation, this is the best time to do so—thanks to generous champions, every contribution will be amplified.
Sonelokimab Promising for Patients with PsA
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
A View from Abroad: The ACR Research Exchange Program
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Type I IFNs in Cutaneous Lupus & Dermatomyositis
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
Meet the Professor: Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a complex, immune-mediated inflammatory disorder characterized by inflammatory back pain and axial arthritis. Typical of other diseases in the spondyloarthritis family, the clinical phenotypes can be diverse, and an array of comorbidities often accompanies the spinal disease. “In this Meet the Professor Session at ACR Convergence 2024,” says Christopher Ritchlin, MD,…
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
Is Intestinal Dysbiosis Associated with RA?
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.
What the Joints Say: Challenges of Tender & Swollen Joint Count Differences
In a new study published in ACR Open Rheumatology, researchers evaluated the impact of tender-swollen joint difference on functional outcomes in early RA and whether associations vary by joint size.
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 816
- Next Page »